CD19 and B-cell non-Hodgkin lymphoma: These indicators were comparable with those in patients with r/r aggressive B-cell lymphomas receiving CD19-targeted CAR-T therapy in such large studies as ZUMA-1 (n=101, ORR=82% CR=54%) and JULIET (n=115, ORR=53% CR=39%).